Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

7 days ago

BOSTON, Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( "Atea" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 ...

Ticker	Sentiment	Impact
AVIR	Neutral	15 %